VIEW NOW: COVID-19 Mitigation Strategies in Pediatric Rare Disease Clinical Trials Virtual Workshop
The Patient-Reported Outcome Consortium’s Rare Disease Subcommittee is pleased to invite you to view the complimentary virtual workshop on COVID-19 Mitigation Strategies in Pediatric Rare Disease Clinical Trials held on May 7, 2021.
Objectives for the workshop included:
- Identifying challenges to conducting pediatric rare disease clinical trials posed by COVID-19
- Presenting a range of strategies aimed at limiting the impact of COVID-19 on the conduct of pediatric rare disease clinical trials
- Presenting a range of mitigation strategies aimed at safely and successfully conducting in-person and remote assessments under pandemic conditions
- Providing an interactive forum for idea sharing related to COVID-19 impact and mitigation strategies across a variety of stakeholders
PDF Version Moderator: Lindsey Murray, PhD, MPH (C-Path)
Presenters: Heather Adams, PhD, Assistant Professor of Neurology and Pediatrics (University of Rochester Medical Center); Kiera Berggren, MA/CCC-SLP, MS, Research Speech-Language Pathologist (Virginia Commonwealth University); Julie Eisengart, PhD, LP, Assistant Professor of Pediatrics, Director, Neurodevelopmental Program in Rare Disease (University of Minnesota); Dawn Phillips, PT, MS, PhD, Director, Clinical Scientist, Outcomes Research (REGENXBIO Inc.); and Adam Shaywitz, MD, PhD, Chief Medical Officer (BridgeBio Gene Therapy)
